Shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC – Get Free Report) have received a consensus rating of “Hold” from the nine ratings firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $14.00.
Several research firms have recently issued reports on BCYC. Jefferies Financial Group restated a “buy” rating and set a $12.00 price objective on shares of Bicycle Therapeutics in a report on Thursday, April 30th. Morgan Stanley reduced their price objective on Bicycle Therapeutics from $13.00 to $12.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 8th. Citigroup restated a “market outperform” rating on shares of Bicycle Therapeutics in a research note on Wednesday, June 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bicycle Therapeutics in a research note on Wednesday, July 8th. Finally, Wall Street Zen raised shares of Bicycle Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 27th.
Read Our Latest Report on Bicycle Therapeutics
Bicycle Therapeutics Price Performance
Bicycle Therapeutics (NASDAQ:BCYC – Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.25). The company had revenue of $0.89 million for the quarter, compared to analyst estimates of $7.50 million. Bicycle Therapeutics had a negative net margin of 344.95% and a negative return on equity of 35.74%. As a group, research analysts expect that Bicycle Therapeutics will post -1.97 EPS for the current fiscal year.
Insider Activity at Bicycle Therapeutics
In other Bicycle Therapeutics news, CEO Kevin Lee sold 5,905 shares of the business’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $4.27, for a total value of $25,214.35. Following the transaction, the chief executive officer directly owned 605,408 shares in the company, valued at $2,585,092.16. The trade was a 0.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 9,977 shares of company stock valued at $42,702. 22.00% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Bicycle Therapeutics
Institutional investors have recently modified their holdings of the stock. Armistice Capital LLC boosted its stake in Bicycle Therapeutics by 8.7% in the fourth quarter. Armistice Capital LLC now owns 3,236,000 shares of the company’s stock valued at $22,911,000 after buying an additional 258,000 shares in the last quarter. Long Focus Capital Management LLC raised its stake in Bicycle Therapeutics by 7.7% during the third quarter. Long Focus Capital Management LLC now owns 1,418,695 shares of the company’s stock worth $10,981,000 after acquiring an additional 101,402 shares in the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new position in Bicycle Therapeutics during the fourth quarter worth about $954,000. Flax Pond Capital LLC bought a new position in shares of Bicycle Therapeutics in the fourth quarter worth about $1,229,000. Finally, Rangeley Capital LLC lifted its holdings in shares of Bicycle Therapeutics by 76.0% in the first quarter. Rangeley Capital LLC now owns 232,260 shares of the company’s stock worth $1,078,000 after acquiring an additional 100,260 shares during the last quarter. 86.15% of the stock is owned by institutional investors.
About Bicycle Therapeutics
Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.
Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.
Read More
- Five stocks we like better than Bicycle Therapeutics
- Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop
- Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs?
- The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story
- Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
